%0 Journal Article
%T A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
%A Jeffrey Cummings
%A Maria Pueyo
%A Philippe Robert
%A St¨¦phanie Galtier
%A Sylvie Bretin
%A Sylvie Gouttefangeas
%A Vjera Holthoff-Detto
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2019
%R 10.1016/j.trci.2019.04.002
%X {"type":"entrez-protein","attrs":{"text":"S47445","term_id":"2132335","term_text":"pir||S47445"}}S47445 is a novel positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors that may emerge as a favorable candidate for the symptomatic treatment of cognitive and depressive disorders in patients suffering from Alzheimer's disease (AD) of mild to moderate severity and with depressive symptoms
%K Alzheimer's disease
%K Positive allosteric AMPA modulator
%K Glutamate
%K Depressive symptoms
%K Neuropsychiatric symptoms
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597919/